Spero Therapeutics, Inc. (SPRO) Form 8-K — Oct 27, 2026
Spero Therapeutics announced that Chief Operating Officer Timothy Keutzer will retire effective December 31, 2026, after 11 years with the company. Spero expects to enter a consulting agreement with Keutzer through approximately February 28, 2027 to support the transition, paid at an hourly rate.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.